logo-loader
viewFeedback PLC

Feedback advancing clinical use of TexRAD after bagging CE mark

Alastair Riddell, chairman of Feedback plc (LON:FDBK) tells Proactive they're now able to crack on with expanding the clinical use of  TexRAD in the treatment of lung cancer across the EU after finally receiving a CE mark for the technology earlier this week.

The award of the CE mark means Feedback can now sell TexRAD Lung to hospitals, satisfying the quality, safety and performance standards required for medical devices in the European Union.

This particular version of the product will help doctors diagnose and treat people with lung cancer, the most common and most deadly form of the disease.

Quick facts: Feedback PLC

Price: 1.03 GBX

LSE:FDBK
Market: LSE
Market Cap: £5.56 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Feedback PLC named herein, including the promotion by the Company of Feedback PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Restructure sees Feedback Plc positioned for growth

Alastair Riddell, chairman of Feedback plc (LON:FDBK), tells Proactive's Andrew Scott they've merged two of their subsidiaries as part of plans to restructure and simplify the business. Feedback snapped up Cambridge Computed Imaging and TexRAD back in 2014 and both have been operating as...

on 19/4/18

2 min read